Anika Therapeutics (ANIK) Cash & Current Investments (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Cash & Current Investments data on file, last reported at $66.8 million in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $66.8 million, down 11.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $66.8 million (down 11.37% YoY), and the FY2025 annual result was $81.2 million, up 2.46% from the prior year.
• Cash & Current Investments fell to $66.8 million in Q1 2026 per ANIK's latest filing, from $81.2 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $123.6 million in Q2 2022 and troughed at $66.8 million in Q1 2026.
• A 5-year average of $96.9 million and a median of $96.6 million in 2024 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2022 and 2025: Cash & Current Investments surged 34.04% in 2022, then slipped 25.17% in 2025.
• A 5-year view of Cash & Current Investments shows it stood at $121.0 million in 2022, then retreated by 21.38% to $95.1 million in 2023, then retreated by 16.7% to $79.2 million in 2024, then grew by 2.46% to $81.2 million in 2025, then retreated by 17.72% to $66.8 million in 2026.
• Business Quant data shows ANIK's Cash & Current Investments at $66.8 million in Q1 2026, $81.2 million in Q4 2025, and $80.2 million in Q3 2025.